Literature DB >> 26648644

Febuxostat.

.   

Abstract

Year:  2015        PMID： 26648644      PMCID： PMC4653982          DOI： 10.18773/austprescr.2015.051

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  4 in total

1.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

3.  Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Authors:  Michael A Becker; H Ralph Schumacher; Patricia A MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  J Rheumatol       Date:  2009-03-13       Impact factor: 4.666

4.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Authors:  H Ralph Schumacher; Michael A Becker; Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Janet Streit; Christopher Lademacher; Nancy Joseph-Ridge
Journal:  Arthritis Rheum       Date:  2008-11-15
  4 in total
  1 in total

1.  Risk of Febuxostat-Associated Myopathy in Patients with CKD.

Authors:  Chung-Te Liu; Chun-You Chen; Chien-Yi Hsu; Po-Hsun Huang; Feng-Yen Lin; Jaw-Wen Chen; Shing-Jong Lin
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-16       Impact factor: 8.237
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.